Born2Grow invests €3m in Implandata

Implandata's previous investors, Peppermint Charité Beteiligungsfonds, Hannover Beteiligungsfonds, High-Tech Gründerfonds (HTGF), KfW Bank and a consortium of business angels, also contributed to the round.

The ophthalmic surgical product start-up plans to use the funds to complete the clinical programme for CE marking of its first product and conduct further studies of additional products in Germany and internationally. The company also stated its intention to bring its products to the US market via the establishment of a fully owned US subsidiary of the same name.

Additionally, the company plans to use the funding to incorporate its pressure sensing technology platform into other ophthalmic surgical procedures and products.

The company has so far raised €6.7m for clinical testing of its diagnostic systems.

Previous funding
Peppermint, Enjoy Venture and KfW's ERP Startfonds invested €1.6m in Implandata's series-A funding round in August 2012. The funding was used to begin a CE trial for its pressure sensor product.

The company held a €1.4m first close of its series-A round in December 2011 led by Hannover, HTGF and a consortium of business angels.

In June 2010, Implandata raised a seed funding round of €700,000 from HTGF, Hannover, a private investor and the two founders. The funding was used for targeted marketing of Implandata's products.

Company
Founded in 2010 and headquartered in Hannover, Implandata is a medical device company that monitors intraocular pressure for the management of glaucoma in patients. According to the company, improved intraocular pressure data can result in personalised care, increase the efficiency of treatments and provide cost-saving measures.

Its current Argos-02 clinical studies focus on intraocular pressure sensors, which continuously monitor eye pressure in glaucoma patients. A pressure sensing implant is placed into the lens during cataract surgery, which allows patients to measure their own intraocular pressure under normal conditions. Collected data is then sent via mobile phone, enabling the eye doctor to remotely monitor the glaucoma therapy and provide alerts in case of uncontrolled pressure.

People
Max Ostermeier is co-founder and general manager of Implandata.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• DACH
• Early-stage
• Healthcare
• Germany
• High-Tech Gründerfonds